What is the ticker symbol for Biogen Inc.?

Biogen Inc. trades as BIIB on the NASDAQ.

What are Biogen Inc.'s marketed drugs?

Top marketed products include Tecfidera, Tysabri, Avonex, Plegridy, Vumerity, fampridine.

Biogen Inc. (BIIB)

NASDAQ 23 marketed · 13 in Phase 3

Quick facts

Ticker	BIIB (NASDAQ)

Marketed products

Tecfidera · Immunology · revenue 2800
Tecfidera works by activating the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation and modulate the immune system.
Tysabri · Immunology · revenue 1600
Natalizumab blocks α4 integrins on leukocytes, preventing their adhesion to VCAM-1 and MAdCAM-1, reducing inflammation in MS and Crohn's disease.
Avonex · Neuroscience · revenue 800
Avonex works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis.
Plegridy · Immunology · revenue 800
Plegridy works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis.
Vumerity · Immunology · revenue 500
Vumerity works by binding to the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation in the central nervous system.
fampridine · Neuroscience · revenue 400
Skyclarys · Other · revenue 300
Skyclarys works by activating the Nrf2 pathway to increase the production of antioxidant proteins that protect cells from damage.
Qalsody · Rare Disease · revenue 200
Qalsody works by binding to the messenger RNA (mRNA) of the Superoxide dismutase 1 (SOD1) gene, preventing its expression and reducing the production of the toxic SOD1 protein associated with ALS.
Zurzuvae · Neuroscience · revenue 100
Zurzuvae works by binding to the GABA A receptor, enhancing the inhibitory effects of GABA to calm overactive neurons.
Aduhelm · Immunology
ADUHELM · Neuroscience
ASA · Cardiovascular; Pain management; Immunology
ASA (acetylsalicylic acid) irreversibly inhibits cyclooxygenase (COX) enzymes to reduce platelet aggregation and inflammation.
Avonex · Neuroscience
BG00002 · Other
BG00002 (natalizumab) · Immunology / Neurology
Natalizumab is a monoclonal antibody that blocks the α4β1 integrin on immune cells, preventing their migration across the blood-brain barrier into the central nervous system.
BG00012 (DMF) · Neurology / Immunology
BG00012 (dimethyl fumarate) activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway to reduce oxidative stress and neuroinflammation.
injectable MS DMT · Neurology / Immunology
Injectable MS DMT refers to disease-modifying therapies for multiple sclerosis administered by injection that work through various immunomodulatory mechanisms to reduce inflammation and slow disease progression.
Interferon beta-1a (Avonex) · Immunology
Interferon beta-1a activates interferon signaling pathways to modulate immune responses and reduce inflammatory activity in the central nervous system.
low immunogenic interferon-beta-1a · Immunology
Low immunogenic interferon-beta-1a activates interferon-beta signaling pathways to modulate immune responses and reduce inflammation in autoimmune diseases.
Spinraza · Other
Spinraza works by binding to a specific genetic sequence to increase production of a protein that helps maintain muscle function.
tetanus diphtheria toxoids vaccine · Immunology
The tetanus diphtheria toxoids vaccine stimulates the immune system to produce antibodies against tetanus and diphtheria toxins, providing protective immunity against these bacterial diseases.
TOFIDENCE · Other
TYSABRI and AVONEX · Immunology / Neurology
TYSABRI blocks α4-integrin to prevent immune cells from crossing the blood-brain barrier, while AVONEX is interferon beta-1a that modulates immune response; together they reduce inflammation in multiple sclerosis.

Phase 3 pipeline

ALKS 8700 · Psychiatry/Neurology
ALKS 8700 is a combination of aripiprazole monohydrate and flupenthixol decanoate designed to provide sustained antipsychotic activity through dopamine modulation.
BG00012 (dimethyl fumarate) · Immunology; Neurology
Dimethyl fumarate activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, which reduces oxidative stress and inflammatory responses in immune cells.
BG9418 (interferon beta-1a) · Immunology
BG9418 is interferon beta-1a, which activates interferon signaling pathways to modulate immune responses and reduce inflammation.
BIIB041 (fampridine) · Neurology
Fampridine is a potassium channel blocker that enhances nerve impulse conduction by blocking potassium efflux, thereby improving motor function in demyelinating diseases.
BIIB041 (Fampridine-SR) · Neurology
Fampridine-SR is a potassium channel blocker that enhances nerve impulse conduction by blocking potassium efflux, thereby improving motor function in patients with multiple sclerosis.
BIIB059 (litifilimab) · Immunology
Litifilimab is a monoclonal antibody that blocks B7-related protein 1 (BR1), an immune checkpoint molecule that suppresses T cell activation.
BIIB122 · Neurology
BIIB122 is a monoclonal antibody that targets and inhibits LINGO-1, a protein that suppresses myelin repair and regeneration in the central nervous system.
exemestane (Aromasin) · Oncology
Exemestane is a steroidal aromatase inhibitor that blocks the enzyme aromatase, reducing estrogen production in postmenopausal women with hormone receptor-positive breast cancer.
Interferon beta type 1a · Immunology
Interferon beta-1a binds to type I interferon receptors on immune cells to enhance antiviral and immunomodulatory responses, reducing inflammation and immune cell infiltration into the central nervous system.
Placebo matching DMF · Neurology
This is a placebo formulation designed to match the appearance and administration characteristics of dimethyl fumarate (DMF) for blinded clinical trial purposes.
Placebo matching DRF
This is a placebo formulation designed to match the appearance and administration characteristics of an active investigational drug in a blinded clinical trial.
Placebo matching fingolimod · Immunology
Fingolimod is a sphingosine-1-phosphate receptor modulator that reduces lymphocyte egress from lymphoid tissues, decreasing their infiltration into the central nervous system.
Standard of Care IST · Neurology
IST is a disease-modifying therapy that targets the immune system to slow disease progression in multiple sclerosis.

Phase 2 pipeline

Baminercept alfa 1
Baminercept alfa 2
Baminercept alfa 3 · Fibrosis, Oncology
Baminercept alfa 3 is a fusion protein that targets and modulates the activity of TGF-beta superfamily members.
Baminercept alfa 4 · Rheumatology
Baminercept alfa 4 is a fusion protein that targets and binds to the soluble form of tumor necrosis factor (TNF) to prevent its interaction with cell surface TNF receptors.
Baminercept alfa 5
BG00010 · Neurology
BG00010 is a monoclonal antibody targeting amyloid beta.
BIIB014 · Oncology
BIIB014 is a monoclonal antibody targeting CD20.
BIIB033
BIIB080
BIIB091 · Oncology
BIIB091 is a monoclonal antibody targeting CD47.
BIIB104 · Neurology
BIIB104 is a selective inhibitor of leucine-rich repeat kinase 2 (LRRK2) that reduces pathological protein aggregation in neuronal cells.
BIIB111
CNV1014802
Interferon Beta Therapy
natalizumab IV
natalizumab SC
non-pegylated interferon
Nusinersen Sodium Injection
Omaveloxolone Capsules, 150 mg
Omaveloxolone Lotion 0.5%
Omaveloxolone Lotion 3%
Omaveloxolone Ophthalmic Suspension 0.5%
Omaveloxolone Ophthalmic Suspension 1%
Omaveloxolone Ophthalmic Suspension 1.0%
Omaveloxolone Opthalmic Suspension 0.5%
SC interferon beta-1a
SC interferon beta-1b
SC Peginterferon beta-1a

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: